Piper Sees 'Re-Birth' For Amarin Shares In 2021, Keeps $19 Price Target

Heading into early 2021, Amarin shares continue to be "repressed and undervalued" ahead of a key binary event of European approval of Vascepa, Piper Sandler analyst Yasmeen Rahimi tells investors in a research note.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.